News & Updates
Filter by Specialty:

COVID-19 variants carry no increased autoimmune sequelae risk
COVID-19 variants delta and omicron BA.1 or BA.2 do not pose a substantial threat of long-term autoimmune complications, except for a modest elevation in inflammatory bowel disease and bullous skin disorders among hospitalized patients during the omicron predominance in Singapore, as shown in a study.
COVID-19 variants carry no increased autoimmune sequelae risk
16 Sep 2024
Fewer CV events after COVID-19 vaccine-related myocarditis
In a nationwide French cohort study, myocarditis attributed to COVID-19 mRNA vaccination causes fewer cardiovascular (CV) events at 18 months of follow-up than that attributed to SARS-CoV-2 infection or myocarditis of conventional aetiologies.
Fewer CV events after COVID-19 vaccine-related myocarditis
13 Sep 2024
Aiming for clinical remission in severe asthma
The introduction of targeted biologic therapies has revolutionized the management of severe asthma, where clinical remission is now viewed as a realistic treatment goal. In an interview with MIMS Doctor, Professor Ken Ka-Pang Chan of the Department of Medicine and Therapeutics, the Chinese University of Hong Kong, discussed updates in the Global Initiative for Asthma (GINA) 2024 Report that reflect recent research findings on clinical remission with biologic therapy. He further highlighted how tezepelumab, a first-in-class monoclonal antibody that targets thymic stromal lymphopoietin (TSLP), may help achieve this goal through its broad action on multiple downstream inflammatory pathways involved in asthma pathophysiology.
Aiming for clinical remission in severe asthma
13 Sep 2024
PVR predicts death in patients with bronchiectasis-associated pulmonary hypertension
Pulmonary vascular resistance (PVR) may be used to distinguish severe (PVR >4 Wood Units) from nonsevere pulmonary hypertension (PVR ≤4 Wood Units) among patients with bronchiectasis-associated pulmonary hypertension (BAPH) and identify those who are at higher risk of mortality, a study suggests.
PVR predicts death in patients with bronchiectasis-associated pulmonary hypertension
04 Sep 2024
Steroid use may increase mortality in acute exacerbation of FILD
A high mortality risk hounds patients with acute exacerbation (AE) of fibrotic interstitial lung disease (FILD) despite treatment with corticosteroids, reports a study, noting that such risk is similar to that seen in those with AE of idiopathic pulmonary fibrosis (IPF).